News

Tascenso ODT, an approved alternative to Gilenya (fingolimod), is now available to multiple sclerosis (MS) patients in the U.S., where it’s being marketed by Cycle Pharmaceuticals. The launch comes about a month after the U.S. Food and Drug Administration approved a 0.5 mg dose of the…

Frequency Therapeutics announced that it is shifting its focus to advancing small molecules that aim to restore myelin, the protective cover around nerve fibers that is damaged and lost with multiple sclerosis (MS). This decision follows the failure of an investigative treatment for people with acquired hearing loss to…

Long-term use of Zeposia (ozanimod) did not adversely affect the heart of relapsing multiple sclerosis (MS) patients treated for one or two years in Phase 3 clinical trials, with no clinically significant changes in cardiac function reported. Data on people enrolled in the two studies were retrospectively evaluated, as the therapy…

Treatment with CNM-Au8, an experimental oral liquid therapy, led to statistically significant improvements in the health of connections between brain regions for people with stable relapsing-remitting multiple sclerosis (RRMS). That’s according to new MRI data from the Phase 2 VISIONARY-MS trial (NCT03536559), which tested CNM-Au8 against a placebo in…

A tailored diet plan from a dietitian may help people with multiple sclerosis (MS) ingest more calcium from foods, which could make their bones stronger and less prone to osteoporosis. That’s according to data from CalciCoach (NCT02664623), a clinical study that compared the amount of dietary calcium consumed…

Using stem cells derived from people with multiple sclerosis (MS), researchers developed cerebral organoids, or “mini-brains,” to better study the cellular and molecular mechanisms leading to the neurodegenerative disorder. Initial analysis showed that patient-derived stem cells, especially those from people with primary progressive MS (PPMS), tend to be…

Datos Health, a remote care automation company, is collaborating with the Shirley Ryan AbilityLab, in Illinois, on a study that will gauge the effectiveness of remote therapy monitoring in patients with various conditions and disorders, including multiple sclerosis (MS). The Shirley Ryan AbilityLab, based in Chicago, provides…

People over 60 with multiple sclerosis (MS) who have stable disease may discontinue their disease-modifying treatments (DMTs) without an added risk of relapses or worsening disability, according to a small study. At that age, only the presence of lesions with active inflammation and an Expanded Disability…

Measuring levels of the protein GFAP in blood can help to predict disability progression that occurs without relapses — so-called silent progression — in people with multiple sclerosis (MS), a new study reports. These findings may have “clinical implications for patient management and development of novel drugs,” the…

FSD Pharma will soon launch a first-in-human trial testing Lucid-21-302, known as Lucid-MS — its novel chemical treatment for multiple sclerosis (MS) — in healthy volunteers. Health Canada has cleared the company to initiate a Phase 1 clinical trial of the investigational therapy, FSD Pharma announced in a…

Treatment with berberine, a compound found in many plants, eased disease severity and showed anti-inflammatory effects in a mouse model of multiple sclerosis (MS), a new study reports. “These results confirmed that treatment with berberine efficiently improved the disease in the animal model of MS,” the researchers wrote, noting…

Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis (RRMS), a small study from Turkey suggests. Over about 2.5 years of the treatment, these pediatric patients experienced no relapses or MRI activity, and their disability level also improved, indicating…

Primary progressive multiple sclerosis (PPMS) is driven by antibodies in the cerebrospinal fluid (CSF), the liquid around the brain and spinal cord — but this is not the case in the more common relapsing forms of MS — a new study done in mice suggests. Researchers say this result…

Nearly half of multiple sclerosis (MS) patients experience swallowing difficulties, which is notably higher than rates seen in the general population, according to a recent review study and meta-analysis. Because swallowing problems, or dysphagia, can lead to serious, sometimes life-threatening, complications, it is important for patients to be routinely…

Using Mayzent (siponimod) and vitamin D3 as a combination therapy was found to improve motor function and promote remyelination — restoring the damaged myelin sheath around nerve fibers —  in a mouse model of multiple sclerosis (MS). “Our results demonstrate for the first time the potential synergistic effects…

To support the wellness journeys of Canadians living with multiple sclerosis (MS), digital healthcare company Sesh is partnering with MS Canada to provide free, unlimited access to its online mental health platform. The partnership allows patients to participate in virtual therapist-led support groups, and kickstarts research efforts…

PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in people with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

FibroBiologics has launched an online crowdfunding campaign to support the development of potential therapies in the company’s pipeline and advance its clinical programs in multiple sclerosis (MS) and other diseases. The campaign was begun in collaboration with StartEngine, an equity crowdfunding platform that facilitates investments in startup companies.

Supplementation with coconut oil and epigallocatechin gallate (EGCG), a green tea extract, in combination with a Mediterranean-style diet, was associated with improvements in balance and gait in people with multiple sclerosis (MS). Those were the findings of a small pilot study in Spain, which also found that all participants,…

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

Researchers were able to image the cerebellum — a small, compact region of the brain that plays key roles in multiple sclerosis (MS) and other diseases — with greater clarity than ever before. Their imaging approach, which used MRI scanners equipped with powerful magnets, may help learn how…

Two alternative treatments for the cognitive challenges people with multiple sclerosis (MS) can face in daily life — cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) — were found to helpful in a clinical trial. Patients randomized to either treatment approach in the REMIND-MS study had fewer…

Rewind Therapeutics has received new investments to support the development of its therapeutic candidates designed to promote remyelination in neurodegenerative diseases like multiple sclerosis (MS). Currently, the company is focused on advancing its lead candidate toward the clinic as it continues to build a pipeline of additional…

A team of scientists at the University of Texas at Austin Dell Medical School are looking to establish best practices for managing multiple sclerosis (MS) in older adults, citing a relative lack of of research on the disease in people older than 50. Led by Leorah Freeman, MD, PhD,…

Researchers have developed a set of criteria to diagnose optic neuritis (ON) — inflammation in the nerve fibers sending signals to and from the eye — and identify whether it is caused by multiple sclerosis (MS) or other conditions. The criteria, developed by an international group of specialists,…

Lapix Therapeutics has met with the U.S. Food and Drug Administration (FDA) to determine how to advance its investigational treatment candidate LPX-TI641 into clinical trials for autoimmune diseases such as multiple sclerosis (MS). The pre-investigational new drug (pre-IND) meeting is usually the first formal one companies seeking to…

The signaling protein fractalkine was found to promote the repair of myelin — the protecting coating around nerve fibers — that is damaged by the mistaken immune attack that leads to multiple sclerosis (MS), a mouse study demonstrated. In an animal model of the disease, the molecule…

TG Therapeutics’ Briumvi (ublituximab-xiiy), a CD20 inhibitor recently approved for adults with relapsing forms of multiple sclerosis (MS), is now commercially available in the U.S., the company announced. The treatment was approved in the U.S. late last year, with indications that include clinically isolated syndrome, relapsing-remitting MS (RRMS),…

Patient dosing has begun in a Phase 2 trial testing Denali Therapeutics‘ investigational oral RIPK1 inhibitor SAR443820 in people with multiple sclerosis (MS). The clinical trial (NCT05630547) seeks to enroll about 168 patients, age 18–60, with either relapsing-remitting MS (RRMS), active and nonactive secondary progressive…

Teenagers with poor sleep quality or insufficient sleep — those who sleep less than seven hours a night — are 40% to 50% more likely to develop multiple sclerosis (MS) later in life than those who get adequate rest, according to a Swedish population-based study. Differences in sleep timing…